|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang Y: Epidemiology of esophageal
cancer. World J Gastroenterol. 19:5598–5606. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Law S and Wong J: Changing disease burden
and management issues for esophageal cancer in the Asia-Pacific
region. J Gastroenterol Hepatol. 17:374–381. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Holmes RS and Vaughan TL: Epidemiology and
pathogenesis of esophageal cancer. Semin Radiat Oncol. 17:2–9.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stanton RA, Gernert KM, Nettles JH and
Aneja R: Drugs that target dynamic microtubules: A new molecular
perspective. Med Res Rev. 31:443–481. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yvon AM, Wadsworth P and Jordan MA: Taxol
suppresses dynamics of individual microtubules in living human
tumor cells. Mol Biol Cell. 10:947–959. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Blagosklonny MV: Prolonged mitosis versus
tetraploid checkpoint: How p53 measures the duration of mitosis.
Cell Cycle. 5:971–975. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dumontet C and Jordan MA:
Microtubule-binding agents: A dynamic field of cancer therapeutics.
Nat Rev Drug Discov. 9:790–803. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ikui AE, Yang CP, Matsumoto T and Horwitz
SB: Low concentrations of taxol cause mitotic delay followed by
premature dissociation of p55CDC from Mad2 and BubR1 and abrogation
of the spindle checkpoint, leading to aneuploidy. Cell Cycle.
4:1385–1388. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Orr GA, Verdier-Pinard P, McDaid H and
Horwitz SB: Mechanisms of Taxol resistance related to microtubules.
Oncogene. 22:7280–7295. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hou Y, Guo T, Wu C, He X and Zhao M:
Effect of shikonin on human breast cancer cells proliferation and
apoptosis in vitro. Yakugaku Zasshi. 126:1383–1386. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Han W, Li L, Qiu S, Lu Q, Pan Q, Gu Y, Luo
J and Hu X: Shikonin circumvents cancer drug resistance by
induction of a necroptotic death. Mol Cancer Ther. 6:1641–1649.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang H, Zhou P, Huang H, Chen D, Ma N, Cui
QC, Shen S, Dong W, Zhang X, Lian W, et al: Shikonin exerts
antitumor activity via proteasome inhibition and cell death
induction in vitro and in vivo. Int J Cancer. 124:2450–2459. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chang IC, Huang YJ, Chiang TI, Yeh CW and
Hsu LS: Shikonin induces apoptosis through reactive oxygen
species/extracellular signal-regulated kinase pathway in
osteosarcoma cells. Biol Pharm Bull. 33:816–824. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Long S, GuangZhi Y, BaoJie G, Wei X,
YanYong H, YingLi W, Yang Z and LiHua L: Shikonin derivatives
protect immune organs from damage and promote immune responses in
vivo in tumour-bearing mice. Phytother Res. 26:26–33. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao Q, Assimopoulou AN, Klauck SM,
Damianakos H, Chinou I, Kretschmer N, Rios JL, Papageorgiou VP,
Bauer R and Efferth T: Inhibition of c-MYC with involvement of
ERK/JNK/MAPK and AKT pathways as a novel mechanism for shikonin and
its derivatives in killing leukemia cells. Oncotarget.
6:38934–38951. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu X and Sun G: Shikonin enhances
Adriamycin antitumor effects by inhibiting efflux pumps in A549
cells. Oncol Lett. 14:4270–4276. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Song J, Zhao Z, Fan X, Chen M, Cheng X,
Zhang D, Wu F, Ying X and Ji J: Shikonin potentiates the effect of
arsenic trioxide against human hepatocellular carcinoma in vitro
and in vivo. Oncotarget. 7:70504–70515. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mukhtar E, Adhami VM and Mukhtar H:
Targeting microtubules by natural agents for cancer therapy. Mol
Cancer Ther. 13:275–284. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Henley D, Isbill M, Fernando R, Foster JS
and Wimalasena J: Paclitaxel induced apoptosis in breast cancer
cells requires cell cycle transit but not Cdc2 activity. Cancer
Chemother Pharmacol. 59:235–249. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Januchowski R, Zawierucha P, Andrzejewska
M, Ruciński M and Zabel M: Microarray-based detection and
expression analysis of ABC and SLC transporters in drug-resistant
ovarian cancer cell lines. Biomed Pharmacother. 67:240–245. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun QL, Sha HF, Yang XH, Bao GL, Lu J and
Xie YY: Comparative proteomic analysis of paclitaxel sensitive A549
lung adenocarcinoma cell line and its resistant counterpart
A549-Taxol. J Cancer Res Clin Oncol. 137:521–532. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao Q, Kretschmer N, Bauer R and Efferth
T: Shikonin and its derivatives inhibit the epidermal growth factor
receptor signaling and synergistically kill glioblastoma cells in
combination with erlotinib. Int J Cancer. 137:1446–1456. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li W, Liu J, Jackson K, Shi R and Zhao Y:
Sensitizing the therapeutic efficacy of taxol with shikonin in
human breast cancer cells. PLoS One. 9:e940792014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Z, Yin J, Li M, Shen J, Xiao Z, Zhao
Y, Huang C, Zhang H, Zhang Z, Cho CH and Wu X: Combination of
shikonin with paclitaxel overcomes multidrug resistance in human
ovarian carcinoma cells in a P-gp-independent manner through
enhanced ROS generation. Chin Med. 14:72019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang Q, Li S, Fu Z, Lin B, Zhou Z, Wang Z,
Hua Y and Cai Z: Shikonin promotes adriamycininduced apoptosis by
upregulating caspase-3 and caspase-8 in osteosarcoma. Mol Med Rep.
16:1347–1352. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Danial NN and Korsmeyer SJ: Cell death:
Critical control points. Cell. 116:205–219. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Aravind L, Dixit VM and Koonin EV:
Apoptotic molecular machinery: Vastly increased complexity in
vertebrates revealed by genome comparisons. Science. 291:1279–1284.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ogura T, Tanaka Y, Tamaki H and Harada M:
Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent
death of human prostate cancer DU145 cells. Int J Oncol.
48:2330–2338. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rong YP, Barr P, Yee VC and Distelhorst
CW: Targeting Bcl-2 based on the interaction of its BH4 domain with
the inositol 1,4,5-trisphosphate receptor. Biochim Biophys Acta.
1793:971–978. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Srivastava RK, Sasaki CY, Hardwick JM and
Longo DL: Bcl-2-mediated drug resistance: Inhibition of apoptosis
by blocking nuclear factor of activated T lymphocytes
(NFAT)-induced Fas ligand transcription. J Exp Med. 190:253–265.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang T, Xu F, Sheng Y, Zhang W and Chen Y:
A targeted proteomics approach to the quantitative analysis of
ERK/Bcl-2-mediated anti-apoptosis and multi-drug resistance in
breast cancer. Anal Bioanal Chem. 408:7491–7503. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Samuel S, Beljanski V, Van Grevenynghe J,
Richards S, Ben Yebdri F, He Z, Nichols C, Belgnaoui SM, Steel C,
Goulet ML, et al: BCL-2 inhibitors sensitize therapy-resistant
chronic lymphocytic leukemia cells to VSV oncolysis. Mol Ther.
21:1413–1423. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Smith ND, Rubenstein JN, Eggener SE and
Kozlowski JM: The p53 tumor suppressor gene and nuclear protein:
Basic science review and relevance in the management of bladder
cancer. J Urol. 169:1219–1228. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xiong Y, Hannon GJ, Zhang H, Casso D,
Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin
kinases. Nature. 366:701–704. 1993. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yew PR and Berk AJ: Inhibition of p53
transactivation required for transformation by adenovirus early 1B
protein. Nature. 357:82–85. 1992. View
Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yonish-Rouach E, Deguin V, Zaitchouk T,
Breugnot C, Mishal Z, Jenkins JR and May E: Transcriptional
activation plays a role in the induction of apoptosis by
transiently transfected wild-type p53. Oncogene. 11:2197–2205.
1995.PubMed/NCBI
|
|
41
|
Wu Y, Mehew JW, Heckman CA, Arcinas M and
Boxer LM: Negative regulation of bcl-2 expression by p53 in
hematopoietic cells. Oncogene. 20:240–251. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
May P and May E: Twenty years of p53
research: structural and functional aspects of the p53 protein.
Oncogene. 18:7621–7636. 1999. View Article : Google Scholar : PubMed/NCBI
|
